Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH

被引:0
|
作者
Fabian Pitoia
Erika Abelleira
Graciela Cross
机构
[1] University of Buenos Aires,Division of Endocrinology–Hospital de Clínicas
来源
Endocrine | 2017年 / 55卷
关键词
Thyroglobulin levels; Remnant ablation; Differentiated thyroid cancer; Excellent response; Preparation mode; Risk of recurrence;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of our study was to evaluate the prognostic value of stimulated thyroglobulin levels at the moment of remnant ablation for predicting an initial excellent or a structural incomplete response to treatment according to the risk of recurrence in patients with differentiated thyroid cancer. Patients were divided into two groups according to the preparation mode for remnant ablation (thyroid hormone withdrawal or recombinant human TSH). We included 219 patients followed-up for at least for 24 months after remnant ablation. The primary endpoint was the best response to initial therapy assessed in the first 9–18 months of follow-up. An excellent response was observed in 45.1 % of patients prepared after recombinant human TSH compared to 44.6 % of patients prepared after thyroid hormone withdrawal (P = NS). The cutoff value of thyroglobulin level after recombinant human TSH for predicting an excellent response was 8 ng/ml (n = 51), with a sensitivity of 73.9 %, and a positive predictive value of 61 %. It was similar for patients with low vs. intermediate to high risk of recurrence. This cutoff value for thyroglobulin level after thyroid hormone withdrawal was 22 ng/ml (n = 168), with a sensitivity of 94.7 % and a positive predictive value of 61.7 %. In the thyroid hormone withdrawal group the thyroglobulin cutoff level was 12 ng/ml for low-risk patients compared to 16 ng/ml for those with intermediate to high risk of recurrence (P = 0.003). The cutoff value of the thyroglobulin level for predicting a structural incomplete response to initial treatment was 20 ng/ml after rhTSH, with a negative predictive value of 91.4 %. This level was higher in thyroid hormone withdrawal group, and it was established at 25 ng/ml, with a negative predictive value of 97.7 %. The stimulated Tg level seems to be different depending on the preparation mode (rhTSH or THW) for RA. It has a high NPV to predict the absence of a structural incomplete response and it is also a good predictor of the initial excellent response and the NED status at the end of follow-up.
引用
收藏
页码:200 / 208
页数:8
相关论文
共 50 条
  • [21] Recombinant Human Thyroid-Stimulating Hormone in Radioiodine Thyroid Remnant Ablation
    Mylonas, Chrystalleni
    Zwas, Shifra T.
    Rotenberg, Galina
    Omry, Gal
    Cohen, Ohad
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (02): : 106 - 109
  • [22] Ablation of thyroid residues with 30 mCi 131I:: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal
    Pacini, F
    Molinaro, E
    Castagna, MG
    Lippi, F
    Ceccarelli, C
    Agate, L
    Elisei, R
    Pinchera, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09): : 4063 - 4068
  • [23] Thyroglobulin levels after recombinant TSH in the follow-up of low-risk patients with differentiated thyroid cancer
    Vlassopoulou, V
    Vassilatou, E
    Botoula, E
    Gripeou, C
    Christoforaki, M
    Tzavara, I
    Thalassinos, N
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 1087 - 1090
  • [24] Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation
    Vrachimis, A.
    Schober, O.
    Riemann, B.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2012, 51 (03): : 67 - 72
  • [25] Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?
    Jeong, Eugene
    Yoon, Joon-Kee
    Lee, Su Jin
    Soh, Euy Young
    Lee, Jeonghun
    Kim, Hyeung Kyoo
    An, Young-Sil
    MEDICINE, 2019, 98 (51)
  • [26] A Comparison of THyroid Hormone Withdrawal and Recombinant Human Thyreotropin in Remnant Ablation with Moderate Activities of Radioiodine
    Kuna, S. Kusacic
    Ciglar, M.
    Despot, M.
    Herceg, G. Horvatic
    Huic, D.
    Bracic, I.
    Dodig, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S112 - S112
  • [27] Clinical Outcome of Low-risk Differentiated Thyroid Cancer Patients after Radioiodine Remnant Ablation and Recombinant Human Thyroid-stimulating Hormone Preparation
    Vianello, F.
    Mazzarotto, R.
    Mian, C.
    Lora, O.
    Saladini, G.
    Servodio, O.
    Basso, M.
    Pennelli, G.
    Pelizzo, M. R.
    Sotti, G.
    CLINICAL ONCOLOGY, 2012, 24 (03) : 162 - 168
  • [28] Follow-up of differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after recombinant human thyrotropin (rhTSH) or thyroid hormone withdrawal
    Elisei, R.
    Corone, C.
    Driedger, A.
    Haugen, B. R.
    Kloos, R. T.
    Magner, J.
    Pacini, F.
    Luster, M.
    Schlumberger, M.
    Sherman, S.
    Pinchera, A.
    Ladenson, P. W.
    HORMONE RESEARCH, 2007, 68 : 33 - 33
  • [29] Follow-up of differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei, R.
    Corone, C.
    Driedger, A.
    Haugen, B.
    Kloos, R.
    Magner, J.
    Pacini, F.
    Luster, M.
    Schlumberger, M.
    Sherman, S.
    Pinchera, A.
    Ladenson, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S207 - S208
  • [30] Ablation of thyroid remnant with 30 mCi 131I in thyroid cancer patients prepared with recombinant human TSH
    Rosario, Pedro Weslley
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2012, 56 (05) : 338 - 340